Brokerages expect Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) to post $10.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Axsome Therapeutics’ earnings, with the lowest sales estimate coming in at $6.00 million and the highest estimate coming in at $15.00 million. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Axsome Therapeutics will report full year sales of $45.90 million for the current year, with estimates ranging from $5.19 million to $80.30 million. For the next year, analysts anticipate that the business will post sales of $194.79 million, with estimates ranging from $132.80 million to $271.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its quarterly earnings data on Monday, May 2nd. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.03). During the same quarter in the previous year, the company earned ($0.78) EPS.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Axsome Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,699,490 shares of the company’s stock valued at $111,730,000 after purchasing an additional 13,868 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Axsome Therapeutics by 2.0% in the fourth quarter. BlackRock Inc. now owns 2,109,622 shares of the company’s stock valued at $79,700,000 after buying an additional 41,559 shares during the last quarter. Fairmount Funds Management LLC raised its holdings in shares of Axsome Therapeutics by 402.4% in the first quarter. Fairmount Funds Management LLC now owns 942,571 shares of the company’s stock valued at $39,013,000 after buying an additional 754,973 shares during the last quarter. Bellevue Group AG raised its holdings in shares of Axsome Therapeutics by 113.9% in the third quarter. Bellevue Group AG now owns 752,945 shares of the company’s stock valued at $24,817,000 after buying an additional 400,924 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 507,485 shares of the company’s stock valued at $19,172,000 after buying an additional 16,055 shares during the last quarter. Institutional investors own 48.46% of the company’s stock.
NASDAQ:AXSM opened at $31.13 on Thursday. Axsome Therapeutics has a 12 month low of $19.38 and a 12 month high of $74.10. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -8.37 and a beta of 2.47. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of 3.36. The company’s 50 day moving average is $35.36 and its 200-day moving average is $33.84.
About Axsome Therapeutics (Get Rating)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.